Centre Georges Francois Leclerc

This study tests whether adding a short course of a MEK inhibitor (mirdametinib) to standard chemoimmunotherapy is safe and effective for people with advanced non-squamous non-small cell lung cancer that has low PDL1 levels. The trial has two parts: first finding the best dose, t…

This study looks at people who developed cancer at a young age (before 40, or before 30 for breast cancer) but had normal results on standard genetic tests. Researchers will use a more advanced technique called exome sequencing to search for new genetic changes that might raise c…

This study is testing whether a more detailed genetic analysis of tumors (called 'complex' exome analysis) helps doctors choose better treatments for people with advanced solid tumors compared to a standard genetic analysis. About 8,000 participants will have their tumor and norm…